Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Shanghai Juncell Therapeutics
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05087745CT.gov A Clinical Study on TIL for the Treatment of Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05142475CT.gov A Study of GC101 TIL in Advanced Breast Cancer (10hospital) | — | Recruiting | — | — | — |
NCT05098184CT.gov A Study of GC101 TIL in Advanced Melanoma (10hospital) | — | Recruiting | — | — | — |
NCT05098197CT.gov A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Iatrogenic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| TIL (this asset) | Shanghai Juncell Therapeutics | Early P1 | C · 39 |
| Velpatasvir | Alexandria University | P4 | BB |
| Autologous Conditioned Plasma | Star Spine and Sport | P4 | BB |
| Sofosbuvir | Alexandria University | P4 | BB |
| Nadroparin | Rijnstate Hospital | P4 | BB |
| Paliperidone | Consorcio Centro de Investigación Biomédica en Red (CIBER) | P4 | BB |
| Nepenthe | Tiva Group | P4 | BB |
| Dexasone | Peking University First Hospital | P4 | BB |
| Pregabalin | Beijing Tiantan Hospital | P2/3 | BB |
+28 more in the Iatrogenic Disease cohort
Other indications for TIL
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | BBB · 72 |
| Ovarian Cancer | — | P2 | BB · 70 |
| Metastatic Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. TIL in Iatrogenic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/til-iatrogenic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →